## Expert Assessment: Closed-Loop FUS Targeting EC-II SST Interneurons
### Druggability: Low (as stated), Device-Based is Viable
Direct pharmacological targeting of EC-II SST interneurons is essentially impossible—systemic agents cannot achieve cell-type specificity in deep cortical structures. The hypothesis correctly pivots to focused ultrasound, which is a reasonable delivery strategy. However, FUS neuromodulation lacks cell-type selectivity; acoustic energy affects all neurons in the focal volume indiscriminately. Claims of selectively activating SST over nearby PV interneurons in EC-II are not supported by current FUS physics. The mechanistic premise that SST, not PV, drives gamma in this specific circuit also conflicts with established literature (gamma is primarily PV-pyramidal feedback-driven).
### Feasibility: Moderate-High for Technology, Low for Specific Mechanism
Closed-loop EEG-triggered FUS neuromodulation is technically feasible—groups at MIT/Harvard and others have demonstrated proof-of-concept in rodents. Human EC-II targeting is achievable (30mm depth, ~2mm resolution with modern arrays). **However**, the mechanistic chain (SST → gamma restoration → tau blockade) requires validation at each step. The critical link—SST dysfunction as the primary gamma disruptor in human AD—remains unproven; PV deficits appear equally prominent in post-mortem AD tissue.
### Competitive Landscape
- **Insightec/Carthera**: FUS BBB opening (FDA-approved for glioblastoma)
- **NeuroPace**: RNS system for closed-loop epilepsy control (FDA-approved)
- **Cerevel/Biogen**: GABAergic modulators targeting interneuron circuits
- **Multiple academic groups**: Gamma entrainment via sensory stimulation in MCI
### Safety Concerns
- Invasive implant for chronic FUS array placement
- Off-target stimulation of perforant path or hippocampal circuits
- Unintended disruption of memory encoding during stimulation
- Unknown effects of chronic gamma-frequency sonic energy on neural tissue
**Verdict**: Innovative but mechanistically premature. The technological platform warrants development for AD, but the specific SST interneuron hypothesis requires substantial preclinical validation before translational investment.